AKTX Projected Dividend Yield

Akari Therapeutics PLC ( NASDAQ : AKTX )

Akari Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for acute and chronic inflammation, specifically through the inhibition of the complement (C5) and leukotriene pathways. Co.'s primary product candidate, nomacopan, inhibits both terminal C5 activation and leukotriene B4 (LTB4). Co.'s clinical targets for nomacopan are orphan inflammatory diseases where the inhibition of both C5 and LTB4 are implicated, including bullous pemphigoid, pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy, and as well as inflammatory conditions in the eye and lung including dry eye, dry AMD and COVID-19 pneumonia.

20 YEAR PERFORMANCE RESULTS